Tandem Diabetes Care Reports Record Q1 Sales Growth

Tandem Diabetes Care ( (TNDM) ) has released its Q1 earnings. Here is a breakdown of the information Tandem Diabetes Care presented to its investors.

Tandem Diabetes Care, a global leader in insulin delivery and diabetes technology, manufactures advanced automated insulin delivery systems aimed at reducing the burden of diabetes management. The company is known for its innovative products like the Tandem Mobi system and the t:slim X2 insulin pump, featuring Control-IQ+ technology.

In its first quarter of 2025, Tandem Diabetes Care reported a significant 22% increase in worldwide sales compared to the same period in 2024, achieving record sales figures. The company also saw a 19% increase in pump sales in the United States, driven by strong shipment growth and improved average selling prices.

Key financial highlights include worldwide sales reaching $234.4 million, with $83.8 million coming from outside the United States. The company’s GAAP gross profit increased to $118.4 million, while the GAAP gross margin improved to 51%. Despite these gains, Tandem reported a GAAP operating loss of $120.9 million and a net loss of $130.6 million. However, the adjusted EBITDA margin improved by 5 points, indicating a positive trend in operational efficiency.

Looking ahead, Tandem Diabetes Care reaffirms its financial guidance for 2025, projecting sales between $997 million and $1.007 billion, with a gross margin of approximately 54%. The company remains focused on achieving sustained double-digit sales growth and profitability, aligning with its long-term financial goals.